Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | MST1R | Q04912 | 1/20 | 0.43 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.43 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7086048 | 0.98 | CA12 (0.53) | CA12CA9MKNK2NTRK2CLK4 | |
| SCHEMBL2729598 | 0.83 | CA12 (0.55) | CA12CA9MKNK2NTRK2CLK4 | |
| SCHEMBL793402 | 0.80 | PARP10 (0.58) | MKNK2CLK4DYRK1BPRKACAGSK3B | |
| Citric Acid SCHEMBL18397977 | 0.80 | ALDH1A1 (0.40) | CA12CA9MKNK2NTRK2CLK4 | |
| SCHEMBL12797192 | 0.77 | CDC7 (0.48) | MKNK2CLK4DYRK1BPRKACAGSK3B | |
| SCHEMBL12469157 | 0.76 | CHRNB2 (0.41) | CA12CA9MKNK2CDC7MAOA | |
| SCHEMBL2016705 | 0.76 | CA12 (0.56) | CA12CA9MKNK2NTRK2CLK4 | |
| SCHEMBL5390472 | 0.75 | TDP2 (0.57) | — | |
| SCHEMBL9040443 | 0.73 | MAOA (0.53) | CA12CA9JAK2MAOAMAOB | |
| SCHEMBL21731307 | 0.72 | CLK4 (0.73) | CA12CA9NTRK2CLK4DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | claimed |
| EP-4444721-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | claimed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| CN-117285525-A | Novel isoxazolyl ether derivatives as GABAA alpha 5PAM | 豪夫迈·罗氏有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-109923113-B | Isoxazolyl ether derivatives as GABA A alpha 5 PAM | 豪夫迈·罗氏有限公司 | 2023-10-13 | — | — | CN | claimed |
| WO-2023107722-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | claimed |
| US-20220411415-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | claimed |
| EP-3551627-B1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN LA ROCHE (CH) | 2022-02-16 | — | — | EP | claimed |
| EP-2391602-B1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-12-04 | — | — | EP | claimed |
| WO-2013126156-A1 | NITRIC OXIDE DONATING SELECTIVE GLUCOCORTICOID RECEPTOR AGONIST COMPOUNDS AND OPHTHALMIC COMPOSITIONS | BAUSCH & LOMB INCORPORATED (US) | 2013-08-29 | — | — | WO | claimed |
| WO-2008060799-A2 | SYNTHESIS OF SELECTED STEREOISOMERS OF CERTAIN SUBSTITUTED ALCOHOLS | BAUSCH & LOMB INCORPORATED (US) | 2008-05-22 | — | — | WO | claimed |
| US-20080064721-A1 | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy | BAUSCH & LOMB INCORPORATED | 2008-03-13 | — | — | US | claimed |
| US-20080058373-A1 | Compositions and Methods for Treating or Preventing Glaucoma or Progression Thereof | VRX HOLDCO LLC | 2008-03-06 | — | — | US | claimed |
| WO-2008027796-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GLAUCOMA OR PROGRESSION THEREOF | BAUSCH & LOMB INCORPORATED (US) | 2008-03-06 | — | — | WO | claimed |
| US-20080031884-A1 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | BAUSCH HEALTH US, LLC | 2008-02-07 | — | — | US | claimed |
| US-20080033008-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFECTIONS AND SEQUELAE THEREOF | BAUSCH HEALTH COMPANIES INC. (CA) | 2008-02-07 | — | — | US | claimed |
| US-20080009437-A1 | Pharmaceutical Compositions and Method for Treating Dry Eye | SALIX PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | claimed |
| EP-1773817-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012374-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033008-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFECTIONS AND SEQUELAE THEREOF | NR3C1, GNRHR, GSR | CA12 3732/4885CA9 3404/4885MKNK2 2877/4885 |
| US-20220411415-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB1, GABRA1 | CA12 3595/4885CA9 2488/4885MKNK2 2415/4885 |
| US-20080031884-A1 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | PTGIR, GCGR, NR3C1 | CA12 4373/4885CA9 2014/4885MKNK2 2540/4885 |
| US-20080009437-A1 | Pharmaceutical Compositions and Method for Treating Dry Eye | NR3C1, GCGR, GPBAR1 | CA12 3190/4885CA9 2131/4885MKNK2 2245/4885 |
| US-20080058373-A1 | Compositions and Methods for Treating or Preventing Glaucoma or Progression Thereof | PTGIR, PTGDR, NR3C1 | CA12 3444/4885CA9 937/4885MKNK2 3109/4885 |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | CA12 3665/4885CA9 4027/4885MKNK2 175/4885 |
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | CA12 2403/4885CA9 2128/4885MKNK2 2448/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CA12 4741/4885CA9 3058/4885MKNK2 163/4885 |
| US-20080064721-A1 | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy | CYSLTR1, LTB4R, CYSLTR2 | CA12 2353/4885CA9 1660/4885MKNK2 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.